丰原药业(000153) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was ¥962,640,018.61, representing an increase of 11.43% compared to ¥863,882,165.30 in the same period last year[4] - Net profit attributable to shareholders was ¥35,754,437.30, up 31.04% from ¥27,285,357.83 year-on-year[4] - Basic earnings per share increased to ¥0.1145, reflecting a growth of 31.01% compared to ¥0.0874 in the previous year[4] - Net profit for Q1 2022 was ¥36,256,746.22, representing a 36.5% increase from ¥26,599,550.42 in Q1 2021[16] - Earnings per share (EPS) for Q1 2022 was ¥0.1145, compared to ¥0.0874 in the previous year, indicating a growth of 30.9%[17] - The company reported a total comprehensive income of ¥33,878,005.49 for Q1 2022, compared to ¥27,488,070.73 in the previous year, an increase of 23.5%[17] Assets and Liabilities - The total assets at the end of the reporting period were ¥4,024,285,151.83, a rise of 5.45% from ¥3,816,330,179.12 at the end of the previous year[4] - Total current assets increased to ¥1,868,813,241.75 from ¥1,694,770,901.78, reflecting a growth of approximately 10.25%[11] - Accounts receivable rose to ¥756,116,505.67 from ¥653,484,276.79, an increase of about 15.77%[11] - Inventory increased to ¥613,609,611.00 from ¥569,531,788.80, showing a growth of approximately 7.73%[12] - Total current liabilities increased to ¥2,124,879,483.68 from ¥1,920,416,837.38, reflecting a growth of approximately 10.65%[12] - The company's total liabilities increased to ¥2,432,705,208.53 from ¥2,258,628,241.31, reflecting a rise of 7.7%[16] - Total equity attributable to shareholders of the parent company rose to ¥1,561,450,729.61, up from ¥1,528,153,114.79, an increase of 2.2%[16] Cash Flow - The net cash flow from operating activities decreased by 12.00% to ¥32,242,266.52 from ¥36,640,215.97 in the same period last year[4] - Cash inflow from operating activities totaled ¥986,358,729.17, compared to ¥929,172,366.57 in the same quarter last year, marking a 6.1% increase[18] - The net cash flow from financing activities rose by 116.76% to ¥5,924,756.15, primarily due to reduced cash payments for interest[7] - Cash inflow from financing activities was CNY 251,716,916.67, down 13.4% from CNY 290,484,611.11 in the previous year[19] - The ending balance of cash and cash equivalents was CNY 238,890,232.29, down from CNY 264,393,855.48, a decrease of 9.7% year-over-year[19] - The company paid CNY 231,100,000.00 in debt repayments, which is a decrease from CNY 269,000,000.00, reflecting a reduction of 14.1%[19] Research and Development - The company's research and development expenses decreased by 51.56% to ¥11,956,114.40 from ¥24,684,328.32 year-on-year[7] - Research and development expenses decreased to ¥11,956,114.40 from ¥24,684,328.32, a reduction of 51.5% year-over-year[16] Shareholder Information - The total number of common shareholders at the end of the reporting period is 32,665[9] - The largest shareholder, Anhui Wuwei Pharmaceutical Factory, holds 11.48% of shares, totaling 35,842,137 shares[9] - The top ten shareholders include several state-owned enterprises, indicating a concentration of ownership[9] Government Subsidies - Government subsidies recognized in the current period amounted to ¥12,170,989.18, a significant increase of 150.99% compared to ¥4,849,180.58 in the previous year[7] Operational Insights - The company is exploring market expansion strategies and new product development initiatives[10] - Total operating costs amounted to ¥922,389,675.57, up from ¥822,318,183.44, reflecting a year-over-year increase of 12.8%[15] - Cash received from sales of goods and services was ¥930,486,210.97, an increase from ¥871,382,239.48, reflecting a growth of 6.8% year-over-year[18] Audit Information - The company did not conduct an audit for the first quarter report[20]